AllianceBernstein
UBX

AllianceBernstein’s Unity Biotechnology UBX Stock Holding History

AllianceBernstein’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,268
Closed -$316K – 3412
2021
Q1 		$316K Buy
5,268
+1,768
+51% +$121K ﹤0.01% 2880
2020
Q4 		$183K Hold
3,500
– – ﹤0.01% 3015
2020
Q3 		$121K Sell
3,500
-2,214
-39% -$140K ﹤0.01% 3050
2020
Q2 		$496K Buy
5,714
+900
+19% +$66.7K ﹤0.01% 2618
2020
Q1 		$279K Buy
4,814
+680
+16% +$42.9K ﹤0.01% 2652
2019
Q4 		$298K Hold
4,134
– – ﹤0.01% 2777
2019
Q3 		$252K Buy
4,134
+680
+20% +$48.1K ﹤0.01% 2861
2019
Q2 		$328K Buy
3,454
+640
+23% +$54.5K ﹤0.01% 2791
2019
Q1 		$228K Buy
2,814
+1,430
+103% +$162K ﹤0.01% 2867
2018
Q4 		$225K Buy
+1,384
New +$184K ﹤0.01% 2845

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AllianceBernstein's UBX Position: Q2 2021 in Review

AllianceBernstein sold out of Unity Biotechnology (UBX) in Q2 2021, closing a stake of 5,268 shares — an estimated $316K sold.

AllianceBernstein first reported a position in UBX in Q4 2018 and held it in 10 quarters. The position peaked at $496K in Q2 2020. 98 funds tracked by Wall St. Rank hold UBX as of Q2 2021.

  • AllianceBernstein reported no remaining Unity Biotechnology position as of Q2 2021 after selling out during the quarter.
  • AllianceBernstein sold 5,268 Unity Biotechnology shares in Q2 2021, an estimated $316K.
  • AllianceBernstein first reported a position in Unity Biotechnology in Q4 2018 and held it in 10 quarters.
  • AllianceBernstein's Unity Biotechnology position peaked at $496K in Q2 2020.
  • 98 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2021.

Based on AllianceBernstein's 13F filing for Q2 2021, filed 30 Jul 2021.